<p></p> <p><strong>About</strong><strong> </strong><strong>Iovance Biotherapeutics, Inc.</strong><strong> </strong> </p> <p><a href="https://www.iovance.com/">Iovance Biotherapeutics</a><u>, Inc.</u> is the global leader in innovating, developing, and delivering tumor infiltrating lymphocyte (TIL) cell therapies for patients with solid tumors. Amtagvi® (lifileucel) is the first FDA-approved, one-time treatment for previously treated advanced melanoma, now approved in three global markets and available at more than 95 authorized treatment centers. The <a href="https://www.iovance.com/our-science/til-platform/">Iovance TIL platform</a> spans registrational trials and next-generation programs in additional solid tumors, including gene-edited and IL-12 tethered TIL therapies, next-generation IL-2, and precision immuno-oncology approaches. As the first and only company to take TIL therapy from concept to a broadly accessible commercial treatment, Iovance operates as an end-to-end cell therapy company, anchored by fully owned, centralized U.S.-based manufacturing that is scaled to serve thousands of cancer patients worldwide each year. For more information, please visit <a href="http://www.iovance.com/">www.iovance.com</a>. </p> <p>Amtagvi® and its accompanying design marks, Proleukin<sup>®</sup>, Iovance<sup>®</sup>, and IovanceCares™ are trademarks and registered trademarks of Iovance Biotherapeutics, Inc. or its subsidiaries. All other trademarks and registered trademarks are the property of their respective owners. </p> <p>Information on Iovance’s broad, industry-leading patent portfolio is available on the Intellectual Property page on <a href="http://www.iovance.com/">www.iovance.com</a>. </p> <p><strong>Overview</strong></p> <p>The Manager, Investor Relations and Corporate Communications, will help drive high-impact communications across investors, media, employees, and other key stakeholders. Reporting to the Senior Director, Corporate Communications, and partnering closely with the Investor Relations and Corporate Communications team, this role will turn company strategy, milestones, and data into clear, compelling communications that support investor engagement, corporate visibility, and internal alignment.</p> <p>This is a hands-on, execution-oriented role for a strong communicator who thrives in a fast-moving public company environment. The ideal candidate brings curiosity, financial acumen, strong project management skills, and the ability to move quickly from insight to action while supporting executive communications, investor engagement, and commercial-stage biotechnology operations.</p> <p><strong>Essential Functions and Responsibilities</strong></p> <ul> <li>Investor Relations & Corporate Communications </li> <li>Create and maintain high-impact investor relations and corporate communications materials, including press releases, earnings scripts, Q&A documents, corporate presentations, FAQs, fact sheets, executive biographies, website content, investor decks, templates, and social media content. </li> <li>Drive internal reviews, approvals, and final deliverables on behalf of the IR and corporate communications team. </li> <li>Support analyst and institutional investor engagement and help advance investor targeting strategies. </li> <li>Monitor metrics and analytics for multi-channel external engagement, media coverage, share of voice, company reputation, market activity, analyst sentiment, peer performance, and consensus estimates, to deliver real-time insights for leadership. </li> <li>Translate key milestones, including earnings, financings, clinical updates, and business developments, into timely, consistent communications for employees, investors, media, and other stakeholders. </li> <li>Own logistics, timelines, briefing materials, and execution support for events led by the team, including internal town halls, media interviews/roundtables and investor days. </li> <li>Support media relations by preparing press materials, tracking coverage, and helping build productive relationships with traditional and social media outlets. </li> <li>Manage agencies and vendors to keep projects moving, on budget, and aligned with investor relations and corporate communications priorities. </li> <li>Cross-Functional & Operational </li> <li>Partner with Finance, Legal, Commercial, R&D, Patient Advocacy, and other teams to deliver accurate, consistent, and compliant communications across filings, disclosures, investor materials, the corporate website, internal meetings, and social media. </li> <li>Improve processes, tools, and workflows to increase the speed, organization, and scalability of the investor relations and corporate communications function. </li> <li>Lead or support priority investor relations and communications projects as business needs evolve. </li> <li>Must adhere to Iovance Biotherapeutics’ core values, policies, procedures, and business ethics.</li> <li>Perform miscellaneous duties as assigned.<strong> </strong></li> </ul> <p><strong>Required Education, Skills, and Knowledge</strong><strong> </strong></p> <ul> <li>8+ years of experience in investor relation